bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
November 5, 2015 11:00 AM EST
Oppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.
Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More
November 5, 2015 8:20 AM EST
bluebird bio (NASDAQ: BLUE) is plunging 13.6% in pre-open trading following an update at ASH.
From the company's press release this morning:
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical... More
November 5, 2015 6:38 AM EST
Oppenheimer analyst Wendy Lam reiterated an Outperform rating and $162 price target on bluebird bio (NASDAQ: BLUE) following Q3 results.
Lam commented, "BLUE reported 3Q15 loss per share of ($1.18) and ended the quarter with $901.7M in cash, cash equivalents, and marketable securities; we have updated our... More
